Medicenna Therapeutics (MDNA) investor relations material

Program updates and clinical progress

• Lead program MDNA11, an IL-2 superagonist, shows 30–50% response rates in patients who failed prior checkpoint inhibitors like Keytruda and Opdivo.

• MDNA11 is engineered for safety and potency, with reduced toxicity and extended half-life, allowing dosing every 2–3 weeks.

• Upcoming data readouts for MDNA11 in melanoma, MSI-high, and TMB-high patients are expected by year-end, potentially supporting phase 2 registration trials.

• Bispecific program MDNA113, combining IL-2 and anti-PD1, targets tumors resistant to current immunotherapies and is planned to enter clinical trials next year.

• Bezoxifas, a late-stage program, doubled survival in phase 2b and is being actively partnered for phase 3 and commercialization.

Platform and pipeline strategy

• The SuperCAN platform, licensed from Stanford, enables creation of next-generation immunotherapies, including bispecifics and extended half-life molecules.

• MDNA11 is being tested both as a monotherapy and in combination with Keytruda, with promising results in previously unresponsive tumor types.

• MDNA213, a bispecific targeting IL-13Rα2, addresses a large market of tumors not benefiting from current checkpoint inhibitors.

• Nonhuman primate data for MDNA113 will support IND-enabling studies, aiming for phase 1/2 trials in the second half of next year.

• The company is actively seeking partners for Bezoxifas and will report progress as it occurs.

Financial and operational highlights

• Headquartered in Toronto, with a market cap of $80M and $21M CAD in cash, funding operations into Q3 next year.

• Insider ownership stands at 22%, and the company is covered by several research analysts.

• Listed on TSX and OTCQX, with ongoing updates planned for the coming months.